ATLASATLAS fair value
CA$10.83
Above fair value · 38% premium
Range: CA$9.74–CA$12Fair valuePrice
Fennec Pharmaceuticals (FRX.TO)
Fennec Pharmaceuticals stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Toronto Stock Exchange · Canada
CA$14.91▲ +4.63%
Prices as of Oct 27, 2026 · CAD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Fennec Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Fennec Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Fennec Pharmaceuticals's fair value at about CA$10.83 per share (reasonable range: CA$9.74 to CA$11.91). At CA$14.91, the stock trades 38% above it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is low. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Fennec Pharmaceuticals a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CA$13.27 and CA$16.42; in 9 out of 10, between CA$10.99 and CA$19.82. Estimated annual volatility is 61%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- CA$503M
- Market cap (USD)
- $358M
- 52-week high
- CA$17.64
- 52-week low
- CA$7.59
- Revenue (12 months)
- $59.2M
- Gross margin
- 93.7%
- Operating margin
- 9.7%
- Net margin
- -5.5%
- Beta
- 1.23
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Fennec Pharmaceuticals sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks FRX.TO has traded between CA$7.59 and CA$17.64. Today it is 15.5% below that high and 96% above its low.
Its beta is 1.23: it tends to move more than the market, both up and down.
About the company
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.
Want to see everything about Fennec Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Fennec Pharmaceuticals (FRX.TO) fair value?
About CA$10.83 per share according to ATLAS (reasonable range: CA$9.74 to CA$11.91). With the stock at CA$14.91, it is 38% above it.
What is the chance FRX.TO goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, FRX.TO ends the month between CA$13.27 and CA$16.42.
How big is Fennec Pharmaceuticals and what is its P/E ratio?
Fennec Pharmaceuticals's market capitalization is CA$503M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is FRX.TO?
ATLAS estimates annual volatility at 61%. In a typical month, half of the outcomes end between CA$13.27 and CA$16.42.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer